Sanofi said it will pursue global regulatory submissions for amlitelimab in atopic dermatitis despite mixed Phase III results that produced divergent outcomes under U.S. and EU analyses. One trial met primary endpoints; a second produced outcomes that fell short under European statistical rules, but Sanofi plans to submit based on the "totality of the data." The move reflects a strategic push to secure a Dupixent successor ahead of looming patent cliffs and highlights regulatory nuance between U.S. and EU assessment frameworks. The company will need to reconcile regional outcome differences and safety observations during review.